Literature DB >> 9551923

CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.

H L Davis1, R Weeratna, T J Waldschmidt, L Tygrett, J Schorr, A M Krieg, R Weeranta.   

Abstract

Unmethylated CpG dinucleotides in bacterial DNA or synthetic oligodeoxynucleotides (ODN) cause B cell proliferation and Ig secretion, monocyte cytokine secretion, and activation of NK cell lytic activity and IFN-gamma secretion in vivo and in vitro. The potent immune activation by CpG ODN suggests possible utility for enhancing immune responses to vaccines. Mice immunized with recombinant hepatitis B virus surface Ag and a CpG ODN as an immune enhancer have titers of Abs against HBsAg (anti-HBs) that are five times higher than those of mice immunized with HBsAg and the standard adjuvant, aluminum hydroxide (alum). Ab titers in mice immunized with HBsAg and both CpG ODN plus alum were 35 times higher than the titers in mice immunized with alum alone, indicating a strong synergistic interaction between the CpG ODN and alum. ODN without CpG motifs had little or no immune-enhancing activity at the doses used herein. Alum induces a Th2 humoral response (mostly IgG1) and no CTL. In contrast, CpG ODN gives a strong Thl response with predominantly IgG2a Abs and CTL, even when mixed with alum. In vitro studies to determine possible mechanisms of CpG immune-enhancing effects show that CpG ODN induce expression of costimulatory molecules on Ag-presenting cells and drive B cell isotype switching in the appropriate cytokine milieu. These studies demonstrate that CpG ODN are promising new immune enhancers for vaccination applications.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9551923

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  144 in total

1.  Antiviral protection after DNA vaccination is short lived and not enhanced by CpG DNA.

Authors:  S Oehen; T Junt; C López-Macías; T A Kramps
Journal:  Immunology       Date:  2000-02       Impact factor: 7.397

2.  CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies.

Authors:  R S Chu; T McCool; N S Greenspan; J R Schreiber; C V Harding
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

Review 3.  The response of human B lymphocytes to oligodeoxynucleotides.

Authors:  H Liang; P E Lipsky
Journal:  Springer Semin Immunopathol       Date:  2000

Review 4.  Signal transduction induced by immunostimulatory CpG DNA.

Authors:  A M Krieg
Journal:  Springer Semin Immunopathol       Date:  2000

Review 5.  Rescue of B cells from apoptosis by immune stimulatory CpG DNA.

Authors:  A M Krieg; A K Yi
Journal:  Springer Semin Immunopathol       Date:  2000

Review 6.  Activation of skin dendritic cells by immunostimulatory DNA.

Authors:  J C Vogel; M C Udey
Journal:  Springer Semin Immunopathol       Date:  2000

Review 7.  Multiple effects of immunostimulatory DNA on T cells and the role of type I interferons.

Authors:  S Sun; X Zhang; D Tough; J Sprent
Journal:  Springer Semin Immunopathol       Date:  2000

Review 8.  Pre-priming: a novel approach to DNA-based vaccination and immunomodulation.

Authors:  H Kobayashi; A A Horner; E Martin-Orozco; E Raz
Journal:  Springer Semin Immunopathol       Date:  2000

Review 9.  The role of CpG in DNA vaccines.

Authors:  M J McCluskie; R D Weeratna; H L Davis
Journal:  Springer Semin Immunopathol       Date:  2000

10.  Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus.

Authors:  Sang-Moo Kang; Richard W Compans
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.